Coronary disease & ACSRandomised controlled trial
Beta-Blocker Interruption or Continuation after Myocardial Infarction
- Randomised controlled trial
- multicentre
- open-label
- non-inferiority
- 49 sites in France
Authors' conclusion
In patients with a history of myocardial infarction, interruption of long-term beta-blocker treatment was not found to be noninferior to a strategy of beta-blocker continuation.
Study context
- Population
- Patients with a history of MI, LVEF ≥40% on long-term beta-blocker, no CV event in the previous 6 monthsmedian follow-up 3.0 years
- Participants
- 3,698 patients
- Comparison
- Beta-blocker interruption vs continuation
- Interruptionn = 1,846
- Continuationn = 1,852reference
- Primary endpoint
- Composite of:
- Death
- Nonfatal MI
- Nonfatal stroke
- Hospitalization for CV reasons
- Follow-up
- Longest (minimum, 1 year)
Primary result
As reported in the abstract
Each group vs continuationRisk difference, percentage points (95% CI)
Interruption
2.8(<0.1 to 5.5)
Non-inferiority margin 3 as printed, not drawn
Each group vs continuationHazard ratio (95% CI)P value
Interruption
1.16(1.01–1.33)
P = 0.44for non-inferiorityNon-inferiority margin 3 as printed, not drawn
Secondary outcomes
Change in quality of life (EQ-5D), main secondary end point
- Beta-blocker interruption did not seem to improve quality of life
Original publication
Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. Published 30 August 2024. doi:10.1056/nejmoa2404204
Summarised from the published abstract; every number is checked against it